Genetic Correlates of Synergy Mechanisms of Daptomycin Plus Fosfomycin in Daptomycin-Susceptible and -Resistant Methicillin-Resistant Staphylococcus aureus (MRSA)
- PMID: 40732039
- PMCID: PMC12299106
- DOI: 10.3390/microorganisms13071532
Genetic Correlates of Synergy Mechanisms of Daptomycin Plus Fosfomycin in Daptomycin-Susceptible and -Resistant Methicillin-Resistant Staphylococcus aureus (MRSA)
Abstract
This study elucidates potential genetic determinants and mechanisms involved in the synergistic effects of daptomycin (DAP) + fosfomycin (FOF) combination therapy. Among 33 clinically derived DAP-susceptible (S)/DAP-resistant (R) isogenic strain pairs, mutations in the mprF gene occurred in 30/33 DAP-R strains, including polymorphisms of L826F (33%) or T345A/L/I (15%). Strain variants of DAP-S CB1483 serially passaged in vitro for 10 days in DAP +/- FOF identified a key non-synonymous mutation in mprF (L826F) only in the DAP monotherapy arm. Interestingly, passage in FOF alone or DAP + FOF prevented the emergence of this mprF mutation following 10-day passage. This L826F mprF polymorphism, associated with a "gain-in-function" phenotype, exhibited increased amounts of lysyl-phosphatidylglycerol (L-PG) in the cell membrane (CM). Transcriptomics revealed a relatively modest number (~10) of distinct genes that were significantly up- or downregulated (≥2 log fold) in both the DAP-S and DAP-R strain pairs upon DAP + FOF exposures (vs. DAP or FOF alone). Of note, DAP + FOF decreased expression of lrgAB and sdrE and increased the expression level of fosB. In a rabbit infective endocarditis (IE) model, the DAP-R CB185 strain treated with DAP +/- FOF showed significantly reduced lrgB expression in vegetations compared with DAP treatment alone. Overall, these findings indicate that DAP + FOF therapy impacts MRSA through multiple specific mechanisms, enhancing bacterial clearance.
Keywords: MRSA; combination therapy; daptomycin; fosfomycin; transcriptomics.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
Synergistic activity of fosfomycin and flucloxacillin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus: in vitro and in vivo assessment.Med Microbiol Immunol. 2025 Jun 21;214(1):32. doi: 10.1007/s00430-025-00841-3. Med Microbiol Immunol. 2025. PMID: 40544222 Free PMC article.
-
Synergy Mechanisms of Daptomycin-Fosfomycin Combinations in Daptomycin-Susceptible and -Resistant Methicillin-Resistant Staphylococcus aureus: In Vitro, Ex Vivo, and In Vivo Metrics.Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0164921. doi: 10.1128/AAC.01649-21. Epub 2021 Oct 25. Antimicrob Agents Chemother. 2022. PMID: 34694870 Free PMC article.
-
Emergence of daptomycin resistance in daptomycin-naïve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms.PLoS One. 2013 Aug 19;8(8):e71151. doi: 10.1371/journal.pone.0071151. eCollection 2013. PLoS One. 2013. PMID: 23990934 Free PMC article.
-
Use of Daptomycin to Manage Severe MRSA Infections in Humans.Antibiotics (Basel). 2025 Jun 18;14(6):617. doi: 10.3390/antibiotics14060617. Antibiotics (Basel). 2025. PMID: 40558207 Free PMC article. Review.
-
Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.Cochrane Database Syst Rev. 2018 Jul 21;7(7):CD009650. doi: 10.1002/14651858.CD009650.pub4. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2022 Dec 13;12:CD009650. doi: 10.1002/14651858.CD009650.pub5. PMID: 30030966 Free PMC article. Updated.
References
-
- Holland T.L., Cosgrove S.E., Doernberg S.B., Jenkins T.C., Turner N.A., Boucher H.W., Pavlov O., Titov I., Kosulnykov S., Atanasov B., et al. ERADICATE Study Group. Ceftobiprole for treatment of complicated staphylococcus aureus bacteremia. N. Engl. J. Med. 2023;389:1390–1401. doi: 10.1056/NEJMoa2300220. - DOI - PubMed
-
- Fowler V.G., Jr., Boucher H.W., Corey G.R., Abrutyn E., Karchmer A.W., Rupp M.E., Levine D.P., Chambers H.F., Tally F.P., Vigliani G.A., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 2006;355:653–665. doi: 10.1056/NEJMoa053783. - DOI - PubMed
-
- Rose W.E., Fallon M., Moran J.J., Vanderloo J.P. Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: Influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression. Antimicrob. Agents Chemother. 2012;56:4422–4427. doi: 10.1128/AAC.00676-12. - DOI - PMC - PubMed
-
- Marty F.M., Yeh W.W., Wennersten C.B., Venkataraman L., Albano E., Alyea E.P., Gold H.S., Baden L.R., Pillai S.K. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J. Clin. Microbiol. 2006;44:595–597. doi: 10.1128/JCM.44.2.595-597.2006. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous